Supplementary Figure S4 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
crossref(2023)
摘要
Supplementary Figure S4: Effect of sorafenib with or without iRGD on MAPK phosphorylation levels in the HepG2 xenografts from the different treatment groups.
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要